NCT01348503View on ClinicalTrials.gov

Lenalidomide in Combination With a Fixed Dose of Sorafenib for the Treatment of Hepatocellular Carcinoma

PHASE1TerminatedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

May 31, 2011

Primary Completion Date

December 31, 2012

Study Completion Date

March 31, 2014

Conditions
Hepatocellular Carcinoma
Interventions
DRUG

Lenalidomide

Escalating doses starting at 15 mg by mouth per day.

DRUG

Sorafenib

Fixed dose of 400 mg by mouth twice a day.

Trial Locations (1)

46202

Indiana University Melvin and Bren Simon Cancer Center, Indianapolis

Sponsors

Collaborators (1)

Celgene Corporation
All Listed Sponsors
collaborator

Celgene Corporation

INDUSTRY

lead

Indiana University School of Medicine

OTHER